Literature DB >> 25541102

Shotgun proteomics reveals possible mechanisms for cognitive impairment in Mucopolysaccharidosis I mice.

Guilherme Baldo1, Daniel Macedo Lorenzini2, Diogenes Santiago Santos2, Fabiana Quoos Mayer3, Sandrine Vitry4, Stephanie Bigou4, Jean Michael Heard4, Ursula Matte5, Roberto Giugliani5.   

Abstract

Mucopolysaccharidosis type I (MPS I) is due to deficient alpha-L-iduronidase (IDUA) which leads to storage of undegraded glycosaminoglycans (GAG). The severe form of the disease is characterized by mental retardation of unknown etiology. Trying to unveil the mechanisms that lead to cognitive impairment in MPS I, we studied alterations in the proteome from MPS I mouse hippocampus. Eight-month old mice presented increased LAMP-1 expression, GAG storage in neurons and glial cells, and impaired aversive and non-aversive memory. Shotgun proteomics was performed and 297 proteins were identified. Of those, 32 were differentially expressed. We found elevation in proteins such as cathepsins B and D; however their increase did not lead to cell death in MPS I brains. Glial fibrillary acid protein (GFAP) was markedly elevated, and immunohistochemistry confirmed a neuroinflammatory process that could be responsible for neuronal dysfunction. We didn't observe any differences in ubiquitin expression, as well as in other proteins related to protein folding, suggesting that the ubiquitin system is working properly. Finally, we observed alterations in several proteins involved in synaptic plasticity, including overexpression of post synaptic density-95 (PSD95) and reduction of microtubule-associated proteins 1A and 1B. These results together suggest that the cognitive impairment in MPS I mice is not due to massive cell death, but rather to neuronal dysfunction caused by multiple processes, including neuroinflammation and alterations in synaptic plasticity.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Brain disease; Cathepsin; Glial fibrillary acidic protein; Hurler syndrome; Mucopolysaccharidosis type I; Ubiquitin

Mesh:

Substances:

Year:  2014        PMID: 25541102     DOI: 10.1016/j.ymgme.2014.12.301

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

1.  Metabolomics profiling reveals profound metabolic impairments in mice and patients with Sandhoff disease.

Authors:  Li Ou; Michael J Przybilla; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2018-09-14       Impact factor: 4.797

2.  Aversive and non-aversive memory impairment in the mucopolysaccharidosis II mouse model.

Authors:  Amanda Stapenhorst Azambuja; Lilian Correa; Bernardo Pappi Gabiatti; Giselle Renata Martins; Álvaro de Oliveira Franco; Maria Flávia Marques Ribeiro; Guilherme Baldo
Journal:  Metab Brain Dis       Date:  2017-09-16       Impact factor: 3.584

3.  Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis.

Authors:  Li Ou; Michael J Przybilla; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2016-10-11       Impact factor: 4.797

Review 4.  Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders.

Authors:  Wenping Li; Stephanie M Cologna
Journal:  Mol Omics       Date:  2022-05-11

5.  CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sandra Motas; Virginia Haurigot; Miguel Garcia; Sara Marcó; Albert Ribera; Carles Roca; Xavier Sánchez; Víctor Sánchez; Maria Molas; Joan Bertolin; Luca Maggioni; Xavier León; Jesús Ruberte; Fatima Bosch
Journal:  JCI Insight       Date:  2016-06-16

6.  Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.

Authors:  Roselena Silvestri Schuh; Esteban Alberto Gonzalez; Angela Maria Vicente Tavares; Bruna Gazzi Seolin; Lais de Souza Elias; Luisa Natalia Pimentel Vera; Francyne Kubaski; Edina Poletto; Roberto Giugliani; Helder Ferreira Teixeira; Ursula Matte; Guilherme Baldo
Journal:  Gene Ther       Date:  2019-12-11       Impact factor: 5.250

7.  Preliminary results of PBA-loaded nanoparticles development and the effect on oxidative stress and neuroinflammation in rats submitted to a chemically induced chronic model of MSUD.

Authors:  Caroline Paula Mescka; Daniella de Moura Coelho; Angela Sitta; Felipe Catarino; Bruna Donida; Andrea Pereira Rosa; Esteban Alberto Gonzalez; Camila Vieira Pinheiro; Fernanda Poletto; Guilherme Baldo; Carlos Severo Dutra-Filho; Carmen Regla Vargas
Journal:  Metab Brain Dis       Date:  2021-02-23       Impact factor: 3.584

Review 8.  Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.

Authors:  Valeria De Pasquale; Anna Moles; Luigi Michele Pavone
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

Review 9.  Innate Immunity in Mucopolysaccharide Diseases.

Authors:  Oriana Mandolfo; Helen Parker; Brian Bigger
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

10.  Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model.

Authors:  Marika Salvalaio; Francesca D'Avanzo; Laura Rigon; Alessandra Zanetti; Michela D'Angelo; Giorgio Valle; Maurizio Scarpa; Rosella Tomanin
Journal:  Int J Mol Sci       Date:  2017-05-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.